Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 83,839 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Not applicable Interventional Accepts healthy volunteers

LLLT for Alopecia of the Eyebrow in Women

NCT04897555
View directory record Official record
Conditions
Alopecia
Interventions
LLLT
Device
Lead sponsor
Freedom Laser Therapy, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Mendham, New Jersey • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 22, 2026, 4:06 AM EDT
Not yet recruiting Not applicable Interventional

Lily's Grace Temporal Interference

NCT07520955
View directory record Official record
Conditions
Epilepsy
Interventions
TES-TI, Sham Stimulation, Structural and Functional MRI
Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Low-dose IL-2 in Established T1D - The "PROREG" Study

NCT03243058
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes, Diabetes, Autoimmune
Interventions
ILT-101 (Aldesleukin; IL-2), Treatment-Placebo Arm, Placebo Arm
Biological · Other
Lead sponsor
Jay S. Skyler
Other
Eligibility
8 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 22, 2026, 4:06 AM EDT
Not listed Not applicable Interventional

Dietary Supplementation on Fat Oxidation

NCT06548048
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Dietary supplement containing plant derived phenolics, Microcrystaline cellulose
Dietary Supplement
Lead sponsor
Brightseed
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Not applicable Interventional

Interpersonal and Social Rhythm Therapy for Adolescents With Bipolar Disorder

NCT00576355
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A), Treatment As Usual (TAU)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
12 Years to 19 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction

NCT01063855
View directory record Official record
Conditions
Erectile Dysfunction, Sexual Dysfunction
Interventions
Placebo, Dapoxetine, PDE5I (phosphodiesterase-5 inhibitor)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Male only
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Decatur, Alabama • Huntsville, Alabama • Englewood, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma

NCT02272855
View directory record Official record
Conditions
Malignant Melanoma
Interventions
HF10 plus Ipilimumab
Biological
Lead sponsor
Takara Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Francisco, California • Atlanta, Georgia • Portland, Oregon + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

Study of Sc-FOS for Pouchitis Prevention

NCT02203955
View directory record Official record
Conditions
Pouchitis
Interventions
Short-Chain Fructooligosaccharide, Maltodextrin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Acupuncture for the Prevention of Postdates Pregnancy

NCT00312585
View directory record Official record
Conditions
Pregnancy
Interventions
Acupuncture, Sham comparator
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 22, 2026, 4:06 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

NCT04340843
View directory record Official record
Conditions
Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions
Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Guadecitabine, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
39
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Burn Scar Appearance After Treatment With Fractional Carbon Dioxide (CO2) Laser

NCT00969215
View directory record Official record
Conditions
Scars
Interventions
Lumenis fractional carbon dioxide laser
Device
Lead sponsor
Moy-Fincher Medical Group
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Oct 22, 2026, 4:06 AM EDT
Recruiting No phase listed Observational

Mucopolysaccharidosis VII Disease Monitoring Program

NCT03604835
View directory record Official record
Conditions
Mucopolysaccharidosis VII, MPS VII, MPS 7, Sly Syndrome
Interventions
No Intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
7
States / cities
Orange, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

NCT03645408
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Exenatide, Sham injection
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 22, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

NCT05188508
View directory record Official record
Conditions
Glioma
Interventions
Pembrolizumab, Olaparib and Temozolomide
Drug · Combination Product
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Not applicable Interventional

Diagnostic Genicular Nerve Block Prior to Radiofrequency Ablation for Knee Osteoarthritis Pain

NCT02578108
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain, Nerve; Lesion
Interventions
genicular nerve diagnostic block with lidocaine (local anesthetic), genicular nerve radiofrequency ablation
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Not applicable Interventional

Walking and Balance Post-TBI

NCT01418976
View directory record Official record
Conditions
Difficulties, Ambulation, Brain Injuries, Traumatic
Interventions
Intensive Mobility Training (IMT)
Behavioral
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

NCT04447417
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab SAR231893
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 22, 2026, 4:06 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

NCT04251117
View directory record Official record
Conditions
HCC
Interventions
GNOS-PV02, INO-9012, Pembrolizumab, CELLECTRA®2000 EP Device
Biological · Drug · Device
Lead sponsor
Geneos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cerebellar rTMS for the Treatment of Schizophrenic Patients

NCT01072617
View directory record Official record
Conditions
Schizophrenia
Interventions
Transcranial magnetic stimulation via MagPro x100 device
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Not applicable Interventional

Luminopia One Pilot Study

NCT02782117
View directory record Official record
Conditions
Amblyopia
Interventions
Luminopia One
Device
Lead sponsor
Luminopia
Industry
Eligibility
4 Years to 12 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Maitland, Florida • Chicago, Illinois • Bloomington, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

NCT04235140
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Months and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Not applicable Interventional

Deep Clinical Trajectory Modeling to Optimize Accrual to Cancer Clinical Trials

NCT06888089
View directory record Official record
Conditions
Cancer
Interventions
AI-assisted MatchMiner Platform
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20,707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

NCT00575068
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
IDEC-114
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
4
States / cities
Tucson, Arizona • Rochester, Minnesota • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Not applicable Interventional

A Clinical Trial Examining the Efficacy of a Novel Acne Treatment Serum

NCT07752368
View directory record Official record
Conditions
Acne, Acne Vulgaris, Skin Health
Interventions
Acne Treatment Serum
Dietary Supplement
Lead sponsor
Parea INC dba Cool as a Cucumber
Industry
Eligibility
24 Years to 47 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 22, 2026, 4:06 AM EDT